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Classical complement pathway activation in membranoprolifera-
tive glomerulonephritis. Levels of components of the classical and
alternative complement pathways and the activity of the C3 ne-
phritic factor (C3NeF) were measured in serum specimens from
patients with type I (subendothelial deposits) and type II (in-
tramembranous dense deposits) membranoproliferative glomerulo-
nephritis (MPGN) and the results compared with the levels in
normal subjects. Although C3 and C5 concentrations were com-
parably depressed in type I and type II, the levels of Clq and C4
were lower in type I and the correlation coefficients between Clq vs.
C4 and C4 vs. C3 were higher than in type II. The profile was
highly suggestive of classical pathway activation. In contrast, in
type II MPGN, factor B levels were lower and C3NeF activity was
more frequently detectable and higher. A feature of interest was
that type 1, as compared to type II, was characterized by signifi-
cantly lower serum concentrations of properdin, higher and more
significant correlation coefficients between serum properdin con-
centrations and those of Clq, C4 and C3, and consistent glomeru-
lar deposition of properdin. The involvement of properdin in type I
may reflect recruitment of a pathway resembling the CI bypass
mechanism, said to involve Cl, properdin, factor B and C3-9.
Vole d'activation classique du complement dans Ia glomerulone-
phrite membrano-proliférative. Les concentrations des composants
des voies classique et alterne du complement et l'activité du facteur
nephritique C3 (C3NeF) ont été mesurés dans des échantillons de
serum de malades atteints de glomérulonéphrite membrano-
proliferative (MPGN) de type I (dépôts sous-endothéliaux) et de
type II (dépôts denses intra-membraneux) et les résultats ont été
compares avec ceux des sujets normaux. Alors que les concentra-
tions de C3 et de CS sont également abaissées dans les types I
et II, les concentrations de Clq et de C4 sont inférieures dans Ic
type I et les coefficients de correlation entre C lq et C4, d'une
part, et C4 et C3, d'autre part, sont meilleures dans le type I. Ce
profil suggère fortement l'activation de Ia voie classique. Au
contraire, dans Ic type II, les concentrations du facteur B sont
plus faibles et l'activitC du C3 NeF est supCrieure et plus souvent
detectable. Un aspect intéressant est le fait que le type I, compare
au type 11, est caractérisé par des concentrations sériques sig-
nificativement inférieures de properdine, par une meilleure cor-
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relation entre Ia concentration de properdine sérique et les con-
centrations de Clq, C4 et C3, et par des dépôts importants de
properdine. L'implication de Ia properdine dans le type I peut
refléter Ia mise en oeuvre d'une voie similaire au mécanisme de
by-pass de Cl dont il est dit qu'elle met en cause Cl, Ia properdine,
Ic facteur B et C3-q.
Ultrastructural studies of the glomeruli in patients
with membranoproliferative glomerulonephritis
(MPGN) have led to the recognition of two distinct
types based on the location of glomerular deposits [1,
2]. Type I MPGN is characterized by subendothelial
deposits and type II by intramembranous dense de-
posits. Both types are characterized by mesangial pro-
liferation and thickening of the capillary walls. In
type I, the thickening of the capillary walls is due to
the subendothelial deposit and to interposition of
mesangial cells between the basement membrane and
the capillary endothelium. Deposits may be abundant
in the mesangiuni. In type II MPGN, the basement
membrane is thickened by electron dense, non-
argyrophilic deposits which are also present in Bow-
man's capsule and the basement membranes of tu-
bules. Mesangial deposits are somewhat less
abundant and mesangial proliferation less rampant
than in type I and mesangial interposition occurs in a
patchy distribution. Subgroups of the two basic types
[2], characterized by excessive lobulation of the
glomeruli or by the presence of crescents, may be the
result of differences in host response or in severity of
the disease.
Although hypocomplementemia frequently accom-
panies this disease, it is by no means consistently
present [3, 4]. Studies of the complement profile in
hypocomplementemic patients, carried out largely be-
fore the heterogeneity of the disease with respect to
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glomerular deposits was recognized, have concluded
that the profile reflects the activation of the alterna-
tive complement pathway. The three early reacting
components of the classical pathway—Cl, C2 and
C4—are usually reported to be in normal concentra-
tion while properdin and factor B may be reduced
[5—9]. Further evidence for alternative pathway acti-
vation is provided by the demonstration that an ac-
tivator of this pathway, the C3 nephritic factor
(C3NeF), is present in the serum [10]. C3NeF in-
itiates a sequence of events leading to C3 cleavage in
the absence of early reacting components of the clas-
sical pathway [9, 11, 12]. Recently, however, some-
what reduced concentrations of Clq and C4 have
been reported in a few patients with MPGN [13, 14].
Further study has shown that reductions in C4 are
usually observed only in patients with type I disease
[2, 14—16] and from this and other evidence, classical
pathway activation has been proposed to be the pri-
mary event in this type [16, 17].
We wish herein to report further differences in the
complement profiles in these two types of MPGN.
Measurement of components of the classical and al-
ternative pathways have indicated that the molecular
events responsible for the hypocomplementemia
differ in the two groups. The most significant differen-
ces were found in the serum concentrations of Clq
and properdin. Correlations between the serum prop-
erdin concentrations and the levels of components of
the classical pathway and of C3 in type I disease
suggest a high degree of interaction.
Methods
Normal human serum. Specimens of normal human
serum (NHS) were collected from 45 healthy adults.
Serum specimens from both normal subjects and
patients were stored at —70°C until used.
Sources of serum from patients. Serum specimens
from 18 patients with MPGN were collected at ran-
dom times. Approximately the same number of se-
rum specimens were obtained from each patient.
Nine patients had type I and nine, type II MPGN.
The specimens were obtained within a few months to
21 yr after the onset of clinical manifestations of the
disease. A number of patients were being treated with
prednisone in an alternate-day schedule at the time
the specimens were obtained [18]. Some of the speci-
mens on four of the patients with type II MPGN were
obtained after renal transplantation. Three of the
four had evidence of recurrence of their disease in the
transplanted kidney and had reduced glomerular fil-
tration rates. One of the patients with type I MPGN
also had moderately severe renal failure. The remain-
der had normal renal function. The clinical-histologi-
cal correlations in the patients treated with alternate-
day prednisone have been described previously [18].
The clinical course of the disease in the untreated
patients corresponded to that described by others [2,
17, 19].
Levels of complement components. Levels of com-
ponents of the classical and alternative pathway were
measured by radial immunodiffusion [20]. The anti-
serum was raised in goats by repeated injection of
purified preparations of antigen incorporated in com-
plete Freund's adjuvant.
The antiserum used for the measurement of C3 was
monospecific for the A antigen of this component
[21]. The antiserum was prepared by immunization
with highly purified preparations of C3c and was
monospecific without absorption. Before measure-
ment of C3, serum specimens were aged sufficiently to
convert the C3 to C3c.
The measurement of C5 employed antiserum pro-
duced by immunization with CS isolated by the
method of Nilsson and Mtiller-Eberhard [22]. The
antiserum was rendered monospecific by absorption
with normal serum heated to 56°C for one hour to
destroy antigenic determinants of CS. The method,
and that for C4 described below, was standardized by
use of a serum with known concentrations of C4 and
CS, kindly supplied by Dr. Peter F. Kohler [23].
Antiserum to C4 was prepared by immunization
with a purified preparation of C4 isolated from serum
by the method of MUller-Eberhard and Biro [24]. The
antiserum was rendered monospecific for C4 by ab-
sorption with Cohn fractions of serum proteins
deficient in C4, kindly supplied by Squibb Labora-
tories, Princeton, NJ.
Antibody to Clq was prepared by immunization
with a preparation of Cl obtained from Cordis Labo-
ratories, Inc., Miami, FL. The antiserum was ren-
dered monospecific by absorption with normal serum
depleted of Clq [25]. The antiserum was standardized
against a specimen of normal human serum. Clq con-
centration was expressed as percent of normal and
the range of normal values was based on measure-
ment of specimens from 45 normal adults.
Antiserum to properdin was raised initially by in-
jection of crude properdin [26]. The antiserum, after
absorption with NHS depleted of properdin by reac-
tion with zymosan at 17°C and 37°C, produced only
one arc when reacted against NHS. This antiserum
was then insolubilized on Sepharose 4B [27], the in-
solubidzed material reacted with NHS and eluates of
this material used for further immunization. The re-
sulting antiserum, after absorption with NHS de-
pleted of properdin, contained antibody in high titer
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which produced a single arc forming a reaction of
identity with that produced by an antiserum mon-
ospecific for properdin kindly supplied by Dr. John
T. Boyer [281.
Antibody to factor B was prepared by injecting a
purified preparation of factor B isolated by the
method of Götze and MUller-Eberhard [29]. The anti-
serum was rendered monospecific by absorption with
serum heated to 56°C for one hour and was stand-
ardized with the serum of known factor B concentra-
tion purchased from Behring Diagnostics, Sommer-
ville, NJ.
Assay for C3NeF. C3NeF activity was measured as
described previously [30]. The activity has been ex-
pressed as percent fall of the level of the B antigen of
C3 occurring with incubation of mixtures of patient
serum and normal serum. No studies were done to
determine the Ca and Mg dependence of the
reaction.
Statistical analysis. Statistical evaluation of the
means of serum concentrations of complement com-
ponents employed Student's t test. Correlations be-
tween serum concentrations of components consid
ered to be physiologically interrelated were assessed
by calculation of correlation coefficients (r) using the
method of least squares. The significance of r was
determined by applying calculated values of t to ap-
propriate tables.
Immunofluorescent studies on renal tissue. Immuno-
histology was performed on 14 specimens of kidney
tissue obtained by needle biopsy [31] and 4 specimens
Fig. 1. Serum concentrations of C3, CS, C4 and Clq in type I and
type II membranoproliferative glomerulonephrifts. The shaded areas
indicate the range (mean 2 SD) of values in 45 specimens of
serum from normal subjects. The means + 2 SM for the specimens
from patients with nephritis are indicated by the horizontal solid
and dashed lines, respectively.
Fig. 2. Serum concentrations of factor B and properdin and the
C3NeF activity in serum specimens from patients with type I and
type II rnembranoproliferative glomerulonephrtis. In the graph of
C3NeF activity, the open circles indicate the highest activity ob-
served for each patient. Otherwise, the data are graphed as in Fig. 1.
obtained by nephrectomy at the time of trans-
plantation. The immunofluorescent technique was de-
scribed previously [32]. The antisera were rendered
monospecific by the methods described above and
were labeled with fluorescein isothiocyanate by the
method of Kawamura [33].
Results
Serum levels of the components of the alternative
and classical pathways. Serum concentrations of the
seven components measured are graphed separately
for type I and type II disease in Figs. 1 and 2, respec-
tively. The values fell both within and below the nor-
mal range indicated by the shaded areas (mean 2
SD). Occasional values were above the normal range.
The mean levels of serum C3 were well below the
normal range in both groups and no significant differ-
ence between the two groups could be demonstrated
(P> 0.05). At least one specimen with a low C3 level
was obtained from each patient except one with type
II disease who had consistently normal levels.
Mean levels of serum C5 were at the lower limit of
the normal range and differed significantly from nor-
mal. However, comparison of the levels in type! and
type II disease showed no significant difference (P>
0.05).
Low C4 levels were observed occasionally in three
patients in each group, and one patient with type I
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disease had a consistently low level over a two-month
period. The mean levels, however, fell within the nor-
mal range but the mean for type I was significantly
lower than that for type II.
The mean levels for Clq were significantly below
the normal range in each group (P < 0.005) and the
mean level for type I was significantly lower (P <
0.001) than that for type II.
Although a few low values for factor B were found
in the type I patients, the mean did not deviate signifi-
cantly from normal. The mean for the type II patients
was lower and differed significantly from both the
mean of the normal serums and from the mean of
type I (P < 0.005).
The mean levels for properdin for both types were
significantly lower than those for normal serum (P <
0.005) and the mean for type I was significantly lower
than that for type II (P < 0.005).
C3NeF. C3NeF activity was demonstrated more
frequently and the activity tended to be greater in
serum specimens from patients with type II disease
(Fig. 2). All patients with this type had C3NeF activ-
ity in at least one specimen whereas among the
patients with type I disease, six (67%) showed no
activity in any specimen.
Correlations between components. Correlation
coefficients (r) calculated for the regressions between
the levels of certain of the components are shown in
Table 1. The data are for 45 specimens from normal
subjects, 40 to 60 specimens from patients with type I
disease and 38 to 70 specimens from patients with
type II disease.
In the normal subjects, the correlation coefficients
tended to be low. None were above 0.38, Those be-
tween C4 and properdin and C4 and C3 were signifi-
cant at the P < 0.05 level.
In patients with type I disease, the correlation
coefficients for six of the pairs were relatively high
and the correlations were significant (P < 0.01). The
best correlations were between C4 and properdin and
C3 and properdin. The two of no significance were
between factor B and properdin and factor B and C3.
Graphic representation of four of the more signifi-
cant correlations are shown in Figs. 3 and 4.
In patients with type II disease, the highly signifi-
cant correlations observed were between C3 and CS
(also highly significant in type I disease), factor B and
C3 and factor B and C3NeF. Other correlations,
highly significant in type I disease, were less signifi-
cant in type'II.
Glomerular immunohislology. Eighteen specimens
of renal tissue from 15 of the patients included in the
study were examined by immunofluorescent tech-
niques for glomerular deposits. Biopsy specimens on
the remaining patients were not studied by this tech-
nique. The results are shown in Table 2. C3 was
detectable in significant amounts in the glomeruli in
all specimens. IgG was present in trace to 2+
amounts in all specimens from patients with type I
disease, but four specimens from patients with type II
disease showed no IgG. The disease was of recent
onset in the one patient with type II disease showing
2+ deposition of IgG. Only one biopsy specimen in
each group showed significant Clq deposition; both
specimens were obtained shortly after the presumed
onset of the disease. Only six of nine biopsy speci-
mens had significant glomerular deposits of proper-
din; all had type I disease.
Discussion
The data give evidence that the extent of in vivo
activation of the complement system in the serum
specimens from patients with type I and type II dis-
ease, judging by the serum concentrations of C3 and
CS and by the correlation coefficients between the
levels of these components, was approximately equal.
Although similar in this respect, the two types dis-
Table 1. Correlations between components of the classical and alternative complement pathways in sera from normal
subjects and patients with type I and type II MPGN
Components
Normal
subjects
Type!
MPGN
Type II
MPGN
N r P N r P N r P
Clq—C4 45 0.12 >0.1 50 0.54 <0.01 70 0.30 <0.02
C4—C3 45 0.34 <0.05 50 0.40 <0.01 70 0.25 <0.05
C3—C5 45 0.04 >0.1 50 0.53 <0.01 70 0.52 <0.01
Clq-..properdin 45 0.03 >0.1 60 0.50 <0.01 55 0.32 <0.05
C4—properdin 45 0.38 <0.05 55 0.63 <0.01 70 0.30 <0.02
C3—properdin
Factor B—properdin
Factor B—C3
45
45
45
0.04
0.13
0.17
>0.1
>0.1
>0.1
57
40
45
0.73
0.18
0.21
<0.01
>0.1
>0.1
70
55
55
0.28
0.14
0.48
<0.02
>0.1
<0.01
Factor B—C3 NeF activity — — — 38 0.48 < 0.01
Calculation included specimens with zero C3NeF activity. Limiting the calculation to specimens with demonstrable C3NeF activity
resulted in N = 25, r = 0.46, P < 0.02.
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higher and more significant than in the type II
patients and only three of the nine patients with this
type had C3NeF detectable in their serum. In con-
sonance with this evidence of predominant classical
pathway activation is the observation by others [34]
of glomerular deposition of Clq and C4 in MPGN,
particularly in type I disease [16, 17].
In the type II patients, low values for Clq were also
observed and, less frequently, low values for C4, but
for neither component were the reductions as great as
in the type I patients. In contrast, factor B levels were
lower and C3NeF, an alternative pathway activator
dependent for C3 cleavage on factor B [9], was more
frequently present.
Of interest is the observation that despite the evi-
dence for classical pathway activation in the type I
disease, serum concentrations of properdin, a com-
ponent of the alternative pathway, were not only
lower than for normal subjects but also were signifi-
cantly lower than those observed in patients with type
II disease. Further, the correlations between levels of
Clq and properdin, C4 and properdin, and C3 and
Fig. 3. Correlations between concentrations of Clq and C4 (upper
graph) and Clq and properdin (lower graph) in type I membrano-
proliferative glomerulonephritis. The shaded areas demarcate the
range of normal values. The regression line was calculated by the
method of least squares.
tinctly differed in the levels of the other complement
components. The profile of the patients with type I
disease was highly suggestive of classical pathway
activation. Clq and C4 concentrations were signifi-
cantly lower than in type II. The data are similar to
those of others [2, 14, 15, 17] indicating low C4 levels
in type I disease. Moreover, the correlation
. .
Fig. 4. Correlations between properdin and C3 (upper graph) andcoefficients between early reacting components (Clq properdin and C4 (lower graph) in type I membranoproliferative
and C4, and C4 and C3) in the type I disease were glomerulonephritis. Data are graphed as in Fig. 3.
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Table 2. Results of glomerular immunofluorescence studies of
renal biopsy specimens and kidneys removed at time of trans-
plantation
Patient
No.
Identifica-
tion code Year lgG Clq C3 Properdin
Type I MPGN
I R0416 1968 ++ NDb
1972 + 0
++
++
ND
+
2 D1216 1974 ++ ++ +++ ++
3 W1812 1970 ++ ND
1974 ++ ND
++
++
ND
+
4 W0112 1971 0 ++ ND
5 S1923 1972 + 0 +++ +
6 S1812 1972 + 0 +++ ++
7 HIOlI 1974 ++ + ++ ++
8 D1619 1971 + 0
Type II MPGN
++ ND
9 D0418 1972
10 DilOl 1971 + ND
Ii J1212 1974 ++ + ++
12 F0408 1968C 0 ND
1973d 0 0
++
++
ND
0
13 C0303 1967C ND ++ ND
14 F1310 1968C 0 ND ++ ND
15 W0401 1970C 0 0 +++ ND
Antibody to the A determinant of
b ND = not done.
End-stage kidney.
d Biopsy of renal transplant.
properdin in the type I disease were more significant
than those for type II. Highly significant correlations
between C3 and properdin have previously been ob-
served by McLean and Michael [35] in MPGN (type
unspecified) as well as in acute poststreptococcal
glomerulonephritis. In contrast, Williams et a! [14]
found a very low correlation coefficient between these
variables in patients with MPGN, most of whom had
type I disease. We know of no explanation for these
discrepant results.
It could be inferred that the material activating the
classical pathway in type I disease is that which con-
stitutes the abundant subendothelial and mesangial
glomerular deposits which are characteristic of the
morphology of this type. The nature of these deposits
is not clear in all cases but, at least in some patients, it
has been inferred to be an immune complex [17]. By
immunofluorescence, glomerular deposits of IgG
were detected in at least trace amounts in all patients
with type I disease in the present series, but others
have reported examples of type I disease in which
IgG was absent from the glomeruli [16, 17]. Assum-
ing an immune complex were present, it would be
expected that Clq would also be deposited. It was,
however, found in significant amounts only in a
patient biopsied shortly after presumed onset of the
disease. In agreement with the observations of Habib
et al [17], glomerular deposits of properdin were con-
sistently observed in the patients with type I disease
but not in those with type II. This together with the
low serum properdin concentrations in this group
would suggest activation of a pathway involving im-
mune complexes and properdin. Such a pathway
might be the Cl bypass mechanism, first described by
May and Frank [36, 37]. These authors demonstrated
that sheep erythrocytes, when heavily sensitized with
Forssman antibody, were lysed by serum deficient in
C4 and C2. Lysis did not occur in such serum with
lightly sensitized cells. The reaction pathway respon-
sible for lysis with heavily sensitized cells was consid-
ered to involve Cl, properdin, factor B and C3
through C9.
Recruitment of this Cl bypass might also explain
the low serum concentrations of properdin and the
glomerular deposition of properdin which are ob-
served in acute poststreptococcal and active lupus
nephritis [5, 13, 14, 35, 38, 39].
Further studies will be necessary, however, before
recruitment of the Cl bypass pathway is completely
acceptable as the explanation of the involvement of
properdin in type I patients. In their studies of this
pathway, May and Frank [36, 37] used only heavily
sensitized red blood cells whereas in nephritis, activa-
tion would be by fluid phase immune complexes. Fur-
ther, their studies did not define the participation of
properdin in the pathway. Although they state that
properdin is involved and include properdin in the
scheme of the pathway, detailed data are not given in
support of its involvement. That fluid phase immune
complexes can activate a pathway involving proper-
din is suggested by the observations of McLean,
Townsend and Michael [40]. These authors reported
that BSA-anti BSA complexes, incubated with nor-
mal serum in vitro, partially deplete the serum of
properdin.
In view of the apparent abundance of complexes in
type I disease and the evidence for classical pathway
activation, it would be of interest to determine
whether the complement activator found occasion-
ally in type I MPGN is an alternative pathway activa-
tor comparable to the C3NeF found in type II disease
or whether it activates the classical pathway.
Although the present studies give some insight into
the nephritogenic mechanism in type I disease, they
do little to elucidate the mechanism producing type II
disease. The low factor B levels in this type may
reflect activation of this protein by C3NeF. C3NeF
activity and C3 levels both correlated with factor B
levels with relatively low but significant correlation
coefficients. The profile thus appears to be influenced
by alternative pathway activation produced by
C3NeF, but evidence is lacking that this complement
reactive factor is directly involved in the pathogenesis
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of the glomerulonephritis. To be explained are the
modest reductions in Clq, C4 and properdin in the
type II patients. The C3NeF reaction does not in-
volve Clq, C4 [II] or properdin [41]. A possible expla-
nation is that the levels of these proteins in type II
reflect the same immune events as are occurring in
type I but on a smaller scale. This would be com-
patible with the relative paucity of mesangial depos-
its, the absence of subendothelial deposits and the
infrequency with which glomerular deposits of prop-
erdin or early reacting components of complement
[16, 17] are observed in type II disease. This explana-
tion is, however, not compatible with the more severe
nature of type II disease and the lower survival rate.
Until more is known of the origin of the deposits in
the basement membranes of the glomeruli, Bowman's
capsule and tubules and their role in pathogenesis,
simplistic explanations of the nephritogenic mecha-
nism in type II disease based on the complement
profile are unwarranted.
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